A Series of Collaborations between Various Pharmaceutical Companies and Regulatory Authorities Concerning the Analysis of Biomolecules Using Capillary Electrophoresis: Additional Instruments/Buffer

• DOI: 10.1365/s10337-007-0437-x
• Publication Date: 2007-11-14T02:31:36Z
• Authors: Brian Nunnally; SungAe Park; Ketaki Patel; Mingfang Hong; Xinfeng Zhang; Shao-Xiong Wang; Brenda Rener; Angelia Reed-Bogan; Oscar Salas-Solano; Wendy Lau; Michel Girard; Heather Carnegie; Virginia Garcia-C...; K. C. Cheng; Ming Zeng; Margaret Ruesch; Ronald Frazier; Claudia Jochheim; Kshama Natarajan; K. Michael Jessop; Mansoor Saeed; Frank Moffatt; Seth Madren; Serigne Thiam; Kevin Altria
• Keywords: 01 natural sciences; 0104 chemical sciences

An international project team (including members from US, Canada and UK) was formed from a number of interested biopharmaceutical companies and regulatory authorities to conduct a cross-organisation collaboration exercise. The results of the first comparison with eight different organisations that used instruments of the same equipment model, the same reagents, and the same methodology has been reported previously [1]. This report represents the addition of other instruments using a different run buffer. The relative migration times were different, as expected, prohibiting a direct comparison between companies. The within-organisation variability was low for both relative migration time (<0.34% RSD% for all companies save one) and the peak area (<5% RSD% for all companies save one) when measuring the purity of a representative IgG sample. The apparent molecular weight of bovine serum albumin was measured with good precision (less than 10% RSD% across all companies) to the theoretical value when all data is utilized (67.5 kDa compared to 66.4 kDa). For a representative IgG sample, the three main components, IgG Light Chain, IgG Non-glycosylated Heavy Chain, and IgG Heavy Chain, could not be separated, specifically the IgG Non-glycosylated Heavy Chain and IgG Heavy Chain. When the IgG Non-glycosylated Heavy Chain and IgG Heavy Chain were combined for all organisations, the fractional peak area for the IgG Light Chain and IgG Non-glycosylated Heavy Chain + IgG Heavy Chain peak also showed excellent agreement, with less than 7.5 and 3.5% RSD%, respectively. The value of this exercise is in demonstrating the reliability of CE for the determination of apparent size of biopharmaceutical proteins. This underpins the appropriate use of such CE data in support of regulatory submissions.